You are here:
Home
NICE guidance
In development
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
In development
Reference number:
GID-TA10994
Expected publication date: TBC
Project information
Project documents
22732-Rozanolixizumab-for-Myasthenia-Gravis-V1.0-FEB2022-NON-CONF.pdf (nihr.ac.uk)
Back to top